Lenalidomid Abz (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4‑CRBN ubiquitin ligase complex, causing selective degradation of transcription factors Ikaros and Aiolos. This action modifies immune signaling, enhances T‑cell and natural‑killer cell activity against tumor cells, and inhibits new blood‑vessel formation that supports cancer growth.

The specific dose of Lenalidomid Abz is determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Healthcare providers set the appropriate strength, frequency, and duration according to approved guidelines and individual patient needs.

Lenalidomid Abz is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception. The safety of the drug during breastfeeding has not been established, and nursing is generally discouraged.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India’s team will verify eligibility, then respond with pricing, availability, shipping details—including any cold‑chain requirements—and necessary import documentation.

Lenalidomid Abz belongs to the immunomodulatory imide drug class, offering a distinct mechanism from proteasome inhibitors or monoclonal antibodies. It is often combined with dexamethasone or other agents to enhance efficacy. Compared with older agents like thalidomide, lenalidomide generally shows improved potency and a more favorable side‑effect profile, though individual response varies.

Lenalidomid Abz should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain stability.

Lenalidomid Abz is taken orally, usually with or without food as directed by the prescribing clinician. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without medical advice.

The most serious risks include severe neutropenia and thrombocytopenia, which can lead to infections or bleeding, and the potential for venous thromboembolism. Rare but critical events such as secondary primary malignancies, Stevens‑Johnson syndrome, and hepatic failure have also been reported, requiring immediate medical attention.

Lenalidomid Abz should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or any component of the formulation, and patients with uncontrolled severe renal impairment unless dose adjustments are made. Clinicians must also avoid prescribing it to patients with a history of serious thrombotic events without appropriate prophylaxis.